JP6322275B2 - ヤヌスキナーゼ阻害剤としてのｎ−（２−シアノヘテロシクリル）ピラゾロピリドン - Google Patents

ヤヌスキナーゼ阻害剤としてのｎ−（２−シアノヘテロシクリル）ピラゾロピリドン Download PDF

Info

Publication number
JP6322275B2
JP6322275B2 JP2016503522A JP2016503522A JP6322275B2 JP 6322275 B2 JP6322275 B2 JP 6322275B2 JP 2016503522 A JP2016503522 A JP 2016503522A JP 2016503522 A JP2016503522 A JP 2016503522A JP 6322275 B2 JP6322275 B2 JP 6322275B2
Authority
JP
Japan
Prior art keywords
alkyl
amino
oxo
dihydro
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016503522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514710A (ja
JP2016514710A5 (enExample
Inventor
デインスモア，クリストフアー
フラー，ピーター
ゲリン，デイビッド
トンプソン，クリストフアー・エフ
プウ，チーンリン
スコット，マーク・イー
カツツ，ジエイソン・デイビッド
クルクラスリヤ，ラビ
クローズ，ジヨシユア・テイー
フアルコン，ダニエル
ブルベイカー，ジエイソン
ズオン，ホーンボー
バイ，ユインフオン
フウ，ジエンミン
コーン，ノーマン
リウ，ユイメイ
ジユヨン，ジーシアーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2016514710A publication Critical patent/JP2016514710A/ja
Publication of JP2016514710A5 publication Critical patent/JP2016514710A5/ja
Application granted granted Critical
Publication of JP6322275B2 publication Critical patent/JP6322275B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016503522A 2013-03-19 2014-03-19 ヤヌスキナーゼ阻害剤としてのｎ−（２−シアノヘテロシクリル）ピラゾロピリドン Active JP6322275B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361803226P 2013-03-19 2013-03-19
US61/803,226 2013-03-19
PCT/CN2014/000298 WO2014146492A1 (en) 2013-03-19 2014-03-19 N-(2-cyano heterocyclyl)pyrazolo pyridones as janus kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2016514710A JP2016514710A (ja) 2016-05-23
JP2016514710A5 JP2016514710A5 (enExample) 2017-04-13
JP6322275B2 true JP6322275B2 (ja) 2018-05-09

Family

ID=51579321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503522A Active JP6322275B2 (ja) 2013-03-19 2014-03-19 ヤヌスキナーゼ阻害剤としてのｎ−（２−シアノヘテロシクリル）ピラゾロピリドン

Country Status (11)

Country Link
US (1) US9957265B2 (enExample)
EP (1) EP2976338B1 (enExample)
JP (1) JP6322275B2 (enExample)
KR (1) KR20150130311A (enExample)
CN (1) CN105189497B (enExample)
AU (1) AU2014234908B2 (enExample)
BR (1) BR112015023878A2 (enExample)
CA (1) CA2901766A1 (enExample)
MX (1) MX2015013414A (enExample)
RU (1) RU2669922C2 (enExample)
WO (1) WO2014146492A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014146246A1 (en) * 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors
WO2016061751A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors
WO2018111663A1 (en) * 2016-12-14 2018-06-21 Merck Sharp & Dohme Corp. Aminopyrazoles as janus kinase inhibitors
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111499592B (zh) * 2020-03-14 2023-06-23 江苏省农用激素工程技术研究中心有限公司 5-氨甲基糖精的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2759227B2 (ja) 1990-09-28 1998-05-28 大鵬薬品工業株式会社 ピラゾロピリジン誘導体
CN1636005A (zh) 1999-06-03 2005-07-06 克诺尔股份有限公司 苯并噻嗪酮和苯并噁嗪酮化合物
AU2003217863B9 (en) 2002-02-28 2009-10-29 Biota Scientific Management Pty Ltd Nucleotide mimics and their prodrugs
TW200406385A (en) 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
JP4139185B2 (ja) 2002-10-17 2008-08-27 京セラ株式会社 配線基板の製造方法
NZ601687A (en) * 2006-01-17 2014-03-28 Vertex Pharma Azaindoles useful as inhibitors of janus kinases
JP5287253B2 (ja) 2007-01-12 2013-09-11 アステラス製薬株式会社 縮合ピリジン化合物
US9346809B2 (en) 2009-07-08 2016-05-24 Leo Pharma A/S Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors
PH12015502575A1 (en) 2010-03-10 2017-04-24 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
WO2012127506A1 (en) 2011-03-22 2012-09-27 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
ES2633793T3 (es) * 2011-09-22 2017-09-25 Merck Sharp & Dohme Corp. Pirazol carboxamidas como inhibidores de quinasa Janus
EP2857400A4 (en) 2012-06-01 2015-12-09 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
WO2014146246A1 (en) * 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors

Also Published As

Publication number Publication date
US9957265B2 (en) 2018-05-01
JP2016514710A (ja) 2016-05-23
EP2976338A4 (en) 2016-08-31
AU2014234908A1 (en) 2015-08-13
RU2015144483A (ru) 2017-04-25
RU2669922C2 (ru) 2018-10-17
US20160272633A1 (en) 2016-09-22
BR112015023878A2 (pt) 2017-07-18
CN105189497A (zh) 2015-12-23
EP2976338A1 (en) 2016-01-27
CN105189497B (zh) 2019-05-03
WO2014146492A1 (en) 2014-09-25
CA2901766A1 (en) 2014-09-25
KR20150130311A (ko) 2015-11-23
EP2976338B1 (en) 2018-01-03
AU2014234908B2 (en) 2017-08-17
MX2015013414A (es) 2016-02-26

Similar Documents

Publication Publication Date Title
JP6110859B2 (ja) ヤヌスキナーゼ阻害剤としてのピラゾールカルボキサミド
EP2788000B1 (en) Pyrrolopyrimidines as janus kinase inhibitors
JP6305510B2 (ja) ヤヌスキナーゼ阻害剤としての非環式シアノエチルピラゾロピリドン
JP6322275B2 (ja) ヤヌスキナーゼ阻害剤としてのｎ−（２−シアノヘテロシクリル）ピラゾロピリドン
EP3209296B1 (en) Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors
JP6412102B2 (ja) ヤヌスキナーゼ阻害剤としてのシクロアルキルニトリルピラゾロピリドン
EP3380474A1 (en) Janus kinases inhibitors, compositions thereof and use thereof
JP2016514709A (ja) ヤヌスキナーゼ阻害剤としてのジェミナル置換シアノエチルピラゾロピリドン
CN105189508B (zh) 作为janus激酶抑制剂的环烷基腈吡唑并吡啶酮
KR20150130309A (ko) 야누스 키나제 억제제로서의 시클로알킬 니트릴 피라졸로 피리돈
KR20150130310A (ko) 야누스 키나제 억제제로서의 같은자리 치환된 시아노에틸피라졸로 피리돈

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180403

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180406

R150 Certificate of patent or registration of utility model

Ref document number: 6322275

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150